about
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic SyndromesEvaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.Does adherence to National Comprehensive Cancer Network guidelines improve pain-related outcomes? An evaluation of inpatient cancer pain management at an academic medical center.Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.Impact of a clinical pathway on appropriate empiric vancomycin use in cancer patients with febrile neutropenia.Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients.Retrospective chart evaluation of hypercalcemia management in oncology patients at the University of Chicago Medical Center.Pepsi® or Coke®? Influence of acid on dasatinib absorption.Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.Medication management in older adults and interprofessional education: a needs assessmentInfections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabineAnalysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribingImpact of a Clinical Decision Support Tool on Cancer Pain Management in Opioid-Tolerant InpatientsPosaconazole-digoxin drug-drug interaction mediated by inhibition of P-glycoproteinImpact of transitioning inpatient chemotherapy regimens to the outpatient settingImplementation of a controlled substance collection receptacleThe ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care
P50
Q37566878-1E2E151B-2F91-429A-A141-518F433B2889Q37717853-E4EF6AEF-BE85-4A49-8773-A09EA593396EQ38179674-BC04BDFB-5238-430D-9AFC-46E7C4C14331Q38917137-93E7C478-2480-4D6E-B218-80E010E77667Q40546513-BEE5D39C-225F-4DF5-9E93-CC75B09D10AEQ47196467-F9F7E374-313D-4A8B-A294-9076D07042CFQ47246413-2B1065A7-374C-407C-BA84-B118042E0B73Q48555829-FDFEF30B-6D74-4204-AC49-73C0A80688E8Q53713010-03A4A6FC-4817-4A24-B1F6-B702968D4274Q57101756-21C5D8F9-6B27-4EC8-AD03-EE78E8B896CDQ84387662-F9C2E105-0AE9-4B3D-B139-B12E7027BA56Q90368668-C47E1AA4-608F-4A5D-9327-97FD10021A04Q90428996-4DDD3082-3362-4011-AA16-8F472CFDAB59Q91800129-B1BDD9E7-B308-4568-8281-4CD02F2D33ACQ91850501-67E88F70-E84D-469D-91CB-4D87F177FA00Q92646894-104E3D1F-B4DD-4084-81F2-9014FC4496B6Q92747926-0719EBC6-14D9-4DB5-BA76-3C9E7A41BD9B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Randall W Knoebel
@en
Randall W Knoebel
@nl
type
label
Randall W Knoebel
@en
Randall W Knoebel
@nl
prefLabel
Randall W Knoebel
@en
Randall W Knoebel
@nl
P108
P108
P31
P496
0000-0002-0166-4955